Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.
Advertisement

Related Content

Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
Wyeth’s Viviant Receives Second “Approvable” Letter For Osteoporosis Prevention
Wyeth Submits More Viviant Data To FDA
Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit
Wyeth Licenses Osteoporosis Drug Targets From Galapagos
Wyeth Says Fracture Data Review Will Delay Viviant Launch
Wyeth Says Fracture Data Review Will Delay Viviant Launch

Topics

Advertisement
UsernamePublicRestriction

Register

PS065950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel